Overview

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
Phase:
Phase 2
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Treatments:
Ifetroban